Drugs / HS-20137
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06844799 | Jun 2025 → Mar 2027 expected | psoriasis | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-03-09 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Results HANSOH PHARMA ANNOUNCES LATE-BREAKING PRESENTATION OF PHASE 2 STUDY ON HS-20137 (ANTI-IL-23P19 ANTIBODY) IN MODERATE TO SEVERE PSORIASIS AT AAD 2025 ANNUAL MEETING hspharm.com ↗
HS-20137 demonstrated strong efficacy and a favorable safety profile in plaque psoriasis patients treated for 28 weeks. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-03-09 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | HANSOH PHARMA ANNOUNCES LATE-BREAKING PRESENTATION OF PHASE 2 STUDY ON HS-20137 (ANTI-IL-23P19 ANTIBODY) IN MODERATE TO SEVERE PSORIASIS AT AAD 2025 ANNUAL MEETING hspharm.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-20137 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06844799 ↗ |
| Modality | Monoclonal antibody | “HS-20137, an Anti-IL-23 Monoclonal Antibody” NCT06844799 ↗ |